FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105369969> ?p ?o ?g. }

• W2105369969 endingPage "1960" @default.
• W2105369969 startingPage "1954" @default.
• W2105369969 abstract "Purpose To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) –positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial. Patients and Methods Patients randomly assigned to receive one year of trastuzumab and one year of observation in the HERA trial were included (n = 3,401). Centrally reviewed estrogen receptor (ER), progesterone receptor (PgR), and HER2 copy numbers were used. First site-specific relapse pattern was evaluated for ILC and invasive ductal carcinoma (IDC). The magnitude of trastuzumab benefit was assessed using the Cox proportional hazards model for disease-free survival (DFS) and overall survival (OS). Results Median follow-up time was 4 years. A total of 187 ILC and 3,213 IDC patients were included. High Allred scores (6 to 8) were more common in patients with ILC than IDC for both ER (36.9% v 22.7%) and PgR (44.1% v 28.5%). A trend toward decreased HER2 copy number was observed in the ILC group. The ILC and IDC subgroups had similar patterns of first site of disease relapse. DFS hazard ratios (HRs) comparing 1 year of trastuzumab versus observation were 0.63 for ILC (95% CI, 0.34 to 1.15) and 0.77 for IDC (95% CI, 0.67 to 0.89; P for interaction = .49). The OS HRs comparing 1 year of trastuzumab versus observation were 0.60 for ILC (95% CI, 0.27 to 1.31) and 0.86 for IDC (95% CI, 0.71 to 1.06; P for interaction = .29). Conclusion In this retrospective analysis, there was no suggestion that patients in the ILC cohort experienced a different magnitude of benefit from adjuvant trastuzumab than those in the IDC cohort." @default.
• W2105369969 created "2016-06-24" @default.
• W2105369969 creator A5007286394 @default.
• W2105369969 creator A5010278367 @default.
• W2105369969 creator A5011012477 @default.
• W2105369969 creator A5014883814 @default.
• W2105369969 creator A5016558677 @default.
• W2105369969 creator A5016987068 @default.
• W2105369969 creator A5020035024 @default.
• W2105369969 creator A5029732013 @default.
• W2105369969 creator A5035383163 @default.
• W2105369969 creator A5036201601 @default.
• W2105369969 creator A5038599053 @default.
• W2105369969 creator A5040290360 @default.
• W2105369969 creator A5057269336 @default.
• W2105369969 creator A5066751484 @default.
• W2105369969 creator A5067552665 @default.
• W2105369969 creator A5068271757 @default.
• W2105369969 creator A5079098518 @default.
• W2105369969 creator A5088697304 @default.
• W2105369969 date "2013-06-01" @default.
• W2105369969 modified "2023-10-18" @default.
• W2105369969 title "Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial" @default.
• W2105369969 cites W1886195314 @default.
• W2105369969 cites W1892496998 @default.
• W2105369969 cites W1964811973 @default.
• W2105369969 cites W1966997182 @default.
• W2105369969 cites W1971272994 @default.
• W2105369969 cites W1997890450 @default.
• W2105369969 cites W2008531855 @default.
• W2105369969 cites W2022034472 @default.
• W2105369969 cites W2031903582 @default.
• W2105369969 cites W2035318542 @default.
• W2105369969 cites W2045324973 @default.
• W2105369969 cites W2046538621 @default.
• W2105369969 cites W2057475768 @default.
• W2105369969 cites W2064404596 @default.
• W2105369969 cites W2086461593 @default.
• W2105369969 cites W2125620887 @default.
• W2105369969 cites W2127362596 @default.
• W2105369969 cites W2139467064 @default.
• W2105369969 cites W2140945784 @default.
• W2105369969 cites W2145257123 @default.
• W2105369969 cites W2148876744 @default.
• W2105369969 cites W2149908785 @default.
• W2105369969 cites W2152872485 @default.
• W2105369969 cites W2165249233 @default.
• W2105369969 cites W2255693290 @default.
• W2105369969 cites W2323254708 @default.
• W2105369969 doi "https://doi.org/10.1200/jco.2012.46.2440" @default.
• W2105369969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23589556" @default.
• W2105369969 hasPublicationYear "2013" @default.
• W2105369969 type Work @default.
• W2105369969 sameAs 2105369969 @default.
• W2105369969 citedByCount "36" @default.
• W2105369969 countsByYear W21053699692013 @default.
• W2105369969 countsByYear W21053699692014 @default.
• W2105369969 countsByYear W21053699692015 @default.
• W2105369969 countsByYear W21053699692016 @default.
• W2105369969 countsByYear W21053699692017 @default.
• W2105369969 countsByYear W21053699692018 @default.
• W2105369969 countsByYear W21053699692019 @default.
• W2105369969 countsByYear W21053699692020 @default.
• W2105369969 countsByYear W21053699692021 @default.
• W2105369969 countsByYear W21053699692022 @default.
• W2105369969 countsByYear W21053699692023 @default.
• W2105369969 crossrefType "journal-article" @default.
• W2105369969 hasAuthorship W2105369969A5007286394 @default.
• W2105369969 hasAuthorship W2105369969A5010278367 @default.
• W2105369969 hasAuthorship W2105369969A5011012477 @default.
• W2105369969 hasAuthorship W2105369969A5014883814 @default.
• W2105369969 hasAuthorship W2105369969A5016558677 @default.
• W2105369969 hasAuthorship W2105369969A5016987068 @default.
• W2105369969 hasAuthorship W2105369969A5020035024 @default.
• W2105369969 hasAuthorship W2105369969A5029732013 @default.
• W2105369969 hasAuthorship W2105369969A5035383163 @default.
• W2105369969 hasAuthorship W2105369969A5036201601 @default.
• W2105369969 hasAuthorship W2105369969A5038599053 @default.
• W2105369969 hasAuthorship W2105369969A5040290360 @default.
• W2105369969 hasAuthorship W2105369969A5057269336 @default.
• W2105369969 hasAuthorship W2105369969A5066751484 @default.
• W2105369969 hasAuthorship W2105369969A5067552665 @default.
• W2105369969 hasAuthorship W2105369969A5068271757 @default.
• W2105369969 hasAuthorship W2105369969A5079098518 @default.
• W2105369969 hasAuthorship W2105369969A5088697304 @default.
• W2105369969 hasBestOaLocation W21053699691 @default.
• W2105369969 hasConcept C121608353 @default.
• W2105369969 hasConcept C126322002 @default.
• W2105369969 hasConcept C143998085 @default.
• W2105369969 hasConcept C207103383 @default.
• W2105369969 hasConcept C2776372563 @default.
• W2105369969 hasConcept C2777863537 @default.
• W2105369969 hasConcept C2779786085 @default.
• W2105369969 hasConcept C2908728163 @default.
• W2105369969 hasConcept C3020375857 @default.
• W2105369969 hasConcept C44249647 @default.
• W2105369969 hasConcept C50382708 @default.
• W2105369969 hasConcept C530470458 @default.

• next